enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. FDA approves 1st new drug for schizophrenia in more ... - AOL

   www.aol.com/fda-approves-1st-drug-schizophrenia...

   The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb ...

3. This FDA-approved drug promises a new way to treat schizophrenia

   www.aol.com/fda-approved-drug-promises-way...

   The nonprofit Institute for Clinical and Economic Review, which analyzes drug prices, said in January that the drug would be cost effective if priced between $16,000 and $20,000 per year.

4. Bristol Myers wins US FDA approval for new type of ...

   www.aol.com/news/us-fda-approves-bristol-myers...

   (Reuters) -The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in decades.

5. SP-624 - Wikipedia

   en.wikipedia.org/wiki/SP-624

   As of August 2024, SP-624 is in phase 2 clinical trials for major depressive disorder and is in phase 1/2 clinical trials for schizophrenia. [1] [2] [3] It is under development by Sirtsei Pharmaceuticals and Arrivo BioVentures. [1] [2] [4] The drug is said to be a small molecule, but its chemical structure does not yet seem to have been ...

6. Xanomeline/trospium chloride - Wikipedia

   en.wikipedia.org/wiki/Xanomeline/trospium_chloride

   In September 2024, it was approved for medical use in the United States. [1] [2] It is the first antipsychotic drug approved by the US Food and Drug Administration (FDA) to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care. [2] [3]

7. Emraclidine - Wikipedia

   en.wikipedia.org/wiki/Emraclidine

   Emraclidine (developmental code names CVL-231, PF-06852231) is an investigational antipsychotic for the treatment of both schizophrenia and Alzheimer's disease psychosis developed by Cerevel Therapeutics. [1] [2] As of August 2024, it is in phase 2 clinical trials. [1] [3]